Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 3/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640 | 0.84 | FFAR1 (0.45) | FFAR4FFAR1ERN1KMT2APDE2A | |
| SCHEMBL6319246 | 0.77 | ERN1 (0.54) | ERN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL28897598 | 0.76 | FFAR4 (0.56) | FFAR4FFAR1KMT2ATAS1R3TAS1R1 | |
| SCHEMBL4966501 | 0.75 | ERN1 (0.39) | ERN1ALDH1A1 | |
| SCHEMBL28014664 | 0.74 | NQO1 (0.45) | ERN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL2505577 | 0.72 | HDAC8 (0.50) | FFAR4FFAR1ERN1ALDH1A1L3MBTL1 | |
| SCHEMBL30453 | 0.69 | LMNA (0.40) | ERN1KMT2APDE2AALDH1A1L3MBTL1 | |
| SCHEMBL1125718 | 0.69 | ALDH1A1 (0.55) | ERN1ALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL3721962 | 0.69 | ALDH1A1 (0.47) | ERN1KMT2AALDH1A1MAPTGAA | |
| SCHEMBL9498221 | 0.69 | NQO1 (0.46) | ERN1KMT2AALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834533-B2 | Process for preparing SGLT2 inhibitors and intermediates thereof | SCINOPHARM TAIWAN, LTD. (TW) | 2017-12-05 | — | — | US | disclosed |
| US-20170240520-A1 | PROCESS FOR PREPARING SGLT2 INHIBITORS AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN, LTD. (TW) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240520-A1 | PROCESS FOR PREPARING SGLT2 INHIBITORS AND INTERMEDIATES THEREOF | SLC5A2, SLC5A1, DPP4 | FFAR4 512/4885FFAR1 1388/4885ERN1 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.